View : 141 Download: 33

A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalanprednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma

Title
A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalanprednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma
Authors
Kim M.K.Kim K.Min C.-K.Kwak J.-Y.Bae S.-B.Yoon S.-S.Lee J.-J.Kim K.H.Nam S.-H.Mun Y.C.Kim H.J.Bae S.H.Shin H.-J.Lee J.-H.Park J.S.Jeong S.H.Lee M.H.Kim Y.-S.Lee H.S.Park K.W.Lee W.-S.Lee S.M.Lee J.-O.Hyun M.S.Jo D.Y.Lim S.-N.Lee J.H.Cho D.-Y.Do Y.R.Kim J.-A.Park S.K.Kim J.S.Kim S.-J.Kim H.Yi H.G.Moon J.H.Choi C.W.Kim S.-H.Joo Y.D.Kim H.-G.Kim B.S.Park M.-R.Song M.-K.Kim S.-Y.
Ewha Authors
문영철
SCOPUS Author ID
문영철scopus
Issue Date
2017
Journal Title
Oncotarget
ISSN
1949-2553JCR Link
Citation
Oncotarget vol. 8, no. 23, pp. 37605 - 37618
Keywords
AgedBortezomibCombinationDrug therapyMultiple myeloma
Publisher
Impact Journals LLC
Indexed
SCIE; SCOPUS WOS scopus
Document Type
Article
Abstract
Bortezomib-melphalan-prednisone (VMP) showed superior efficacy versus MP as first-line treatment for transplantation-ineligible multiple myeloma (MM). This study investigated the efficacy of VMP for Korean patients with MM. Overall, 177 MM patients received 9 cycles of VMP in this prospective, multicenter, observational study. The primary endpoint was 2-year progression-free survival (PFS). Thirty-nine (22%) patients were aged ≥ 75 years and 83 (47.4%) patients had International Staging System stage III. A median of 5 cycles were delivered. Overall response rate (ORR) was 72.9%, and complete response (CR) rate was 20.3%. With a median follow-up of 11.9 months, median PFS was 17 months. The 2-year PFS and overall survival (OS) rates were 29.2% and 80.0%, respectively. Median OS was not reached. PFS was significantly different depending on performance status (Eastern Cooperative Oncology Group < 2 vs. ≥ 2; p = 0.0002), β2-microglobulin level (< 5.5 vs. = 5.5 mg/L; p = 0.0481), and cumulative dose of bortezomib (< 35.1 vs. = 35.1 mg/ m2; p < 0001). The common adverse events (AEs) were in line with the well-known toxicity profiles associated with VMP. In conclusion, VMP is a feasible and effective front-line treatment for transplantineligible older patients with MM in Korea. Continuing therapy with prompt adjustment of treatment according to AEs may be important to improve outcomes of elderly patients. © Kim et al.
DOI
10.18632/oncotarget.16790
Appears in Collections:
의과대학 > 의학과 > Journal papers
Files in This Item:
A prospective, open-label, multicenter, observational study.pdf(1.81 MB) Download
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE